Gene therapy for
advanced coronary artery disease

XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.

Latest News

Press Release: January 26, 2023
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina
More >>

See Our Pipeline

XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>

Research & Development

XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>